
Moderna stock rises 3% despite Citigroup downgrade over valuation concerns
Moderna shares climbed 3% even after Citigroup downgraded the stock to Sell, citing high valuation following a 222% rise since positive melanoma vaccine trial results. The market seems optimistic about Moderna's personalized cancer vaccine pipeline, ...




